NHL Steers Journalist to Music

You may have read Jamie Reno's columns in SI, People Magazine, and Newsweek where he still writes today. In 1996, Reno was diagnosed with Non-Hodgkin's Lymphoma. After chemotherapy in 1997, he achieved remission but the cancer returned in 1999. At that time, he participated in a clinical trial of Bexxar, one of the new monoclonal antibodies I wrote about earlier. Since his treatments he has remained in remission.



His cancer experience moved him to write songs. He has been a musician since his high school days. Reno's music has flowed into three albums: My Side of Paradise in 2000, Reunion in 2001 and recently All American Music with over seven other top artists.



Jamie is an inspiration to all lymphoma survivors. If you would like to know more, you can visit his personal website.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap